See more : Veritiv Corporation (VRTV) Income Statement Analysis – Financial Results
Complete financial analysis of Biocept, Inc. (BIOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biocept, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- GTPL Hathway Limited (GTPL.NS) Income Statement Analysis – Financial Results
- Arnoldo Mondadori Editore S.p.A. (0KAV.L) Income Statement Analysis – Financial Results
- Investar Holding Corporation (ISTR) Income Statement Analysis – Financial Results
- Career Technology (Mfg.) Co., Ltd. (6153.TW) Income Statement Analysis – Financial Results
- Juntendo Co.,Ltd. (9835.T) Income Statement Analysis – Financial Results
Biocept, Inc. (BIOC)
About Biocept, Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.86M | 61.25M | 27.46M | 5.53M | 3.25M | 5.07M | 3.22M | 609.91K | 133.42K | 134.25K | 109.29K | 1.05K |
| Cost of Revenue | 28.44M | 37.76M | 21.34M | 10.98M | 10.05M | 9.35M | 6.92M | 4.60M | 2.17M | 2.33M | 1.20M | 17.32K |
| Gross Profit | -2.58M | 23.49M | 6.12M | -5.45M | -6.80M | -4.28M | -3.70M | -3.99M | -2.04M | -2.20M | -1.09M | -16.27K |
| Gross Profit Ratio | -9.99% | 38.34% | 22.30% | -98.56% | -209.26% | -84.37% | -114.70% | -653.58% | -1,526.91% | -1,635.56% | -999.56% | -1,546.58% |
| Research & Development | 6.16M | 4.96M | 5.22M | 4.70M | 4.47M | 3.36M | 2.71M | 2.86M | 4.50M | 3.09M | 6.56M | 8.85M |
| General & Administrative | 16.11M | 12.61M | 9.97M | 6.97M | 7.07M | 7.19M | 6.56M | 5.69M | 5.20M | 2.51M | 2.06M | 2.73M |
| Selling & Marketing | 7.13M | 8.32M | 6.40M | 5.94M | 5.91M | 6.34M | 5.05M | 3.88M | 2.14M | 148.90K | 785.32K | 672.93K |
| SG&A | 23.24M | 20.93M | 16.37M | 12.91M | 12.99M | 13.53M | 11.61M | 9.57M | 7.34M | 2.66M | 2.85M | 3.40M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.40M | 25.89M | 21.59M | 17.61M | 17.46M | 16.90M | 14.33M | 12.42M | 11.84M | 5.75M | 9.41M | 12.25M |
| Cost & Expenses | 57.84M | 63.66M | 42.93M | 28.59M | 27.51M | 26.24M | 21.25M | 17.02M | 14.01M | 8.08M | 10.61M | 12.27M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 316.00K | 290.00K | 2.34M | 2.08M | 310.98K | 0.00 | 0.00 | 0.00 | 0.00 | 2.07M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.66M | 2.64M | 1.00M | 773.31K | 800.91K | 575.72K | 322.03K | 261.41K | 251.20K | 266.55K | 365.57K | 369.31K |
| EBITDA | -30.33M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.68M | -10.57M | -12.24M |
| EBITDA Ratio | -117.29% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,719.30% | -9,671.01% | -1,163,859.41% |
| Operating Income | -31.98M | -2.41M | -15.47M | -23.06M | -24.26M | -21.17M | -18.03M | -16.41M | -13.87M | -7.94M | -10.50M | -12.27M |
| Operating Income Ratio | -123.69% | -3.93% | -56.33% | -417.05% | -746.35% | -417.76% | -559.25% | -2,690.70% | -10,399.07% | -5,917.86% | -9,610.37% | -1,166,444.49% |
| Total Other Income/Expenses | -229.00K | -290.00K | -2.34M | -2.08M | -310.98K | -431.41K | -372.23K | -537.12K | -1.99M | -1.29M | -1.76M | -1.36M |
| Income Before Tax | -32.21M | -2.70M | -17.81M | -25.14M | -24.57M | -21.61M | -18.40M | -16.95M | -15.86M | -9.23M | -12.26M | -13.63M |
| Income Before Tax Ratio | -124.57% | -4.41% | -64.84% | -454.69% | -755.92% | -426.27% | -570.79% | -2,778.76% | -11,891.12% | -6,877.26% | -11,216.80% | -1,295,483.46% |
| Income Tax Expense | -125.00K | 125.00K | -764.58K | -523.33K | 1.89K | 7.62K | 2.05K | 1.61K | 1.51K | 800.00 | 800.00 | 800.00 |
| Net Income | -32.09M | -2.82M | -17.04M | -24.61M | -24.57M | -21.61M | -18.40M | -16.95M | -15.87M | -9.23M | -12.26M | -13.63M |
| Net Income Ratio | -124.09% | -4.61% | -62.06% | -445.23% | -755.98% | -426.42% | -570.86% | -2,779.03% | -11,892.25% | -6,877.86% | -11,217.53% | -1,295,559.51% |
| EPS | -56.78 | -5.73 | -43.16 | -357.54 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| EPS Diluted | -56.78 | -5.73 | -43.16 | -357.41 | -2.63K | -7.07K | -17.29K | -23.28K | -96.74K | -55.29K | -73.41K | -81.61K |
| Weighted Avg Shares Out | 565.13K | 492.53K | 394.84K | 68.85K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
| Weighted Avg Shares Out (Dil) | 565.13K | 492.53K | 394.84K | 68.87K | 9.33K | 3.06K | 1.06K | 728.00 | 164.00 | 167.00 | 167.00 | 167.00 |
Biocept reports unaudited net revenue of $61.2 million for 2021
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022
Biocept Appoints Philippe Marchand as Chief Operating Officer
Biocept outlines how its CNSide cerebrospinal fluid assay could improve treatment options for brain cancers
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
Biocept appoints Samuel Riccitelli as its interim CEO and Antonino Morales as interim CFO
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer
Biocept appoints Darrell Taylor as its new chief compliance officer
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
Source: https://incomestatements.info
Category: Stock Reports